X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The results of IMB’s inactivated SARS-CoV-2 vaccine, have shown that the intradermal 3rd boost allowed for robust and sustained (>6mo) immunogenicity with a favorable safety (no fever and only mild injection site redness and swelling).
Lead Product(s): Inactivated SARS-CoV-2 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: YNC Medical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2022
Details:
NanoPass is partnering with Emergex for multiple COVID vaccine LD PepGNP-SARSCoV2, to demonstrate that its drug delivery platform, the MicronJet® 600 can reduce the dose of any vaccine as well as improve immune responses using equivalent doses.
Lead Product(s): LD PepGNP-SARSCoV2
Therapeutic Area: Infections and Infectious Diseases Product Name: LD PepGNP-SARSCoV2
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Emergex Vaccines Holding
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
